Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically- or cytologically-confirmed diagnosis of advanced solid tumor.~2. Willing to provide tumor tissue for PD-L1 biomarker analysis.~3. At least one measurable lesion according to RECIST 1.1.~4. ECOG performance status of 0 to 1.~5. Life expectancy of more than 12 weeks.~6. Signing the informed consent forms.~7. Adequate bone marrow, liver and renal function.~Exclusion Criteria:~1. Subjects with untreated central nervous system (CNS) metastases.~2. Subjects with an active, known or suspected autoimmune disease.~3. Subjects with clinically significant cardiovascular and cerebrovascular diseases.~4. Subjects with high blood pressure who cannot be controlled well with antihypertensive drugs.~5. Subjects with previous digestive tract bleeding history within 3 months or evident gastrointestinal bleeding tendency.~6. Subjects with arterial / venous thrombosis events occurred within 6 months of the first dose.~7. Subjects who have previously received anti-PD-1 / PD-L1 monoclonal antibody, anti-CTLA-4 monoclonal antibody, and VEGFR small molecule inhibitor therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- camrelizumab combined with famitinib (Type: EXPERIMENTAL): Participants will receive camrelizumab on Day 1of each cycle and famitinib qd up to 2 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).